Spravato (esketamine) is a nasal spray that contains the drug esketamine, a form of ketamine. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) who have taken an oral antidepressant but have not responded adequately [1][2].
How does Spravato work for depression?
Spravato works differently from traditional antidepressants. It targets the glutamate system in the brain, which is involved in mood regulation. By modulating glutamate, Spravato is thought to help rapidly restore synaptic connections in brain regions affected by depression, leading to improvements in mood and a reduction in suicidal thoughts [1][2].
What is the difference between ketamine and esketamine?
Ketamine is a racemic mixture, meaning it contains both R-ketamine and S-ketamine. Esketamine is the S-enantiomer of ketamine, which is believed to be the primary active form responsible for the antidepressant effects [1]. Spravato specifically contains esketamine [1][2].
How is Spravato administered?
Spravato is administered as a nasal spray and must be taken under the supervision of a healthcare provider in a certified medical office or clinic [1][2]. Patients are monitored for at least two hours after administration due to the potential for sedation and dissociative side effects [2].
What are the risks and side effects associated with Spravato?
Spravato carries a risk of serious side effects, including sedation, dissociation, abuse, and misuse [1][2]. Patients may experience temporary cognitive impairment, changes in perception, or an altered sense of reality. It can also cause elevated blood pressure, which requires monitoring [1]. Due to these risks, Spravato is available only through a restricted distribution system known as the Spravato REMS (Risk Evaluation and Mitigation Strategy) [2].
When does Spravato's patent exclusivity expire?
Information on specific patent expiry dates for Spravato is available through resources like DrugPatentWatch.com [3]. These patents are crucial for determining when generic versions of the drug might become available [3].
Can biosimilars or generics be developed for Spravato?
The development of generic or biosimilar versions of Spravato depends on the expiry of its patents and the regulatory pathways for such products. For drugs like esketamine, a generic version would be subject to FDA approval processes [3].